Page last updated: 2024-08-05 11:13:49
proline derivative
An amino acid derivative resulting from reaction of proline at the amino group or the carboxy group, or from the replacement of any hydrogen of proline by a heteroatom. The definition normally excludes peptides containing proline residues.
ChEBI ID: 26273
Members (12)
| Member | Definition | Role |
|---|
| 1-(7-methyl-5-oxo-[1,3,4]thiadiazolo[3,2-a]pyrimidin-2-yl)-N-(4-methylphenyl)-2-pyrrolidinecarboxamide | | 1-(7-methyl-5-oxo-[1,3,4]thiadiazolo[3,2-a]pyrimidin-2-yl)-N-(4-methylphenyl)-2-pyrrolidinecarboxamide |
| 1-[(2-chlorophenyl)methyl]-N-[3-(N-ethyl-3-methylanilino)propyl]-5-oxo-2-pyrrolidinecarboxamide | | 1-[(2-chlorophenyl)methyl]-N-[3-(N-ethyl-3-methylanilino)propyl]-5-oxo-2-pyrrolidinecarboxamide |
| 1-aminoproline | | D-1-Amino-2-pyrrolidinecarboxylic acid |
| 2-[[(4-methyl-2-thiazolyl)amino]-oxomethyl]-1-pyrrolidinecarboxylic acid 2-methylpropyl ester | | 2-[[(4-methyl-2-thiazolyl)amino]-oxomethyl]-1-pyrrolidinecarboxylic acid 2-methylpropyl ester |
| 4-methylproline | | L-trans-4-Methyl-2-pyrrolidinecarboxylic acid |
| anatibant | | Anatibant |
| byl719 | | (2S)-N1-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)-4-pyridinyl]-2-thiazolyl]pyrrolidine-1,2-dicarboxamide |
| clindamycin | | N-[2-chloro-1-[3,4,5-trihydroxy-6-(methylthio)-2-oxanyl]propyl]-1-methyl-4-propyl-2-pyrrolidinecarboxamide |
| N-[(4-fluorophenyl)methyl]-1-[(4-methylphenyl)methyl]-5-oxo-2-pyrrolidinecarboxamide | | N-[(4-fluorophenyl)methyl]-1-[(4-methylphenyl)methyl]-5-oxo-2-pyrrolidinecarboxamide |
| N1-cyclohexyl-N2-cyclopropylpyrrolidine-1,2-dicarboxamide | | N1-cyclohexyl-N2-cyclopropylpyrrolidine-1,2-dicarboxamide |
| N2-(3-chloro-4-methylphenyl)-N1-(4-methoxyphenyl)pyrrolidine-1,2-dicarboxamide | | N2-(3-chloro-4-methylphenyl)-N1-(4-methoxyphenyl)pyrrolidine-1,2-dicarboxamide |
| relcovaptan | | (2S)-1-[[(2R,3S)-5-chloro-3-(2-chlorophenyl)-1-(3,4-dimethoxyphenyl)sulfonyl-3-hydroxy-2H-indol-2-yl]-oxomethyl]-2-pyrrolidinecarboxamide |
Research
Studies (396)
| Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
|---|
| pre-1990 | 3 (0.76) | 18.7374 |
| 1990's | 43 (10.86) | 18.2507 |
| 2000's | 72 (18.18) | 29.6817 |
| 2010's | 147 (37.12) | 24.3611 |
| 2020's | 131 (33.08) | 2.80 |
Study Types
| Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
|---|
| Trials | 38 (8.84%) | 5.53% |
| Reviews | 21 (4.88%) | 6.00% |
| Case Studies | 13 (3.02%) | 4.05% |
| Observational | 1 (0.23%) | 0.25% |
| Other | 357 (83.02%) | 84.16% |